Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2007 1
2008 1
2010 1
2011 1
2012 1
2013 1
2014 2
2015 3
2016 2
2018 2
2019 4
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Results by year
Filters applied: . Clear all
Page 1
Pulmonary sarcoidosis.
Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU. Spagnolo P, et al. Lancet Respir Med. 2018 May;6(5):389-402. doi: 10.1016/S2213-2600(18)30064-X. Epub 2018 Apr 3. Lancet Respir Med. 2018. PMID: 29625772 Review.
The severity of pulmonary sarcoidosis ranges from incidentally discovered radiographic abnormalities in asymptomatic patients to a chronic progressive disease that is refractory to treatment. ...
The severity of pulmonary sarcoidosis ranges from incidentally discovered radiographic abnormalities in asymptomatic patients to a chroni
Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going?
Hayes GE, Novak-Frazer L. Hayes GE, et al. J Fungi (Basel). 2016 Jun 7;2(2):18. doi: 10.3390/jof2020018. J Fungi (Basel). 2016. PMID: 29376935 Free PMC article. Review.
Chronic pulmonary aspergillosis (CPA) is estimated to affect 3 million people worldwide making it an under recognised, but significant health problem across the globe, conferring significant morbidity and mortality. ...Sometimes weight loss and fatigue are pr
Chronic pulmonary aspergillosis (CPA) is estimated to affect 3 million people worldwide making it an under recognised, but sig
Characterisation of fatigue and its substantial impact on health status in a large cohort of patients with chronic pulmonary aspergillosis (CPA).
Al-Shair K, Muldoon EG, Morris J, Atherton GT, Kosmidis C, Denning DW. Al-Shair K, et al. Respir Med. 2016 May;114:117-22. doi: 10.1016/j.rmed.2016.03.020. Epub 2016 Apr 2. Respir Med. 2016. PMID: 27109821 Free article.
INTRODUCTION: Fatigue is a prominent disabling symptom in several pulmonary diseases. Its impact on health status in patients with chronic pulmonary aspergillosis (CPA) has not been investigated. METHODS: A total of 151 CPA patients attending the National …
INTRODUCTION: Fatigue is a prominent disabling symptom in several pulmonary diseases. Its impact on health status in patients with …
Chronic Nodular Pulmonary Aspergillosis in a Patient with Rheumatoid Arthritis.
Ito Y, Tanigawa M, Takemura T, Iwamoto K, Nigi A, Sasano H, Itani H, Kondo S, Tokui T, Nakamura S, Miyazaki Y. Ito Y, et al. Intern Med. 2019;58(7):979-984. doi: 10.2169/internalmedicine.1918-18. Epub 2019 Apr 1. Intern Med. 2019. PMID: 30930349 Free PMC article.
Chronic pulmonary aspergillosis, which features nodular lesions known as Aspergillus nodules, is a relatively uncommon disorder. We herein report a case of slowly progressing chronic multiple nodular pulmonary aspergillosis in a 59-year-old man with rh
Chronic pulmonary aspergillosis, which features nodular lesions known as Aspergillus nodules, is a relatively uncommon disorde
Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis.
Kosmidis C, Rodriguez-Goncer I, Rautemaa-Richardson R, Richardson MD, Moore CB, Denning DW. Kosmidis C, et al. J Antimicrob Chemother. 2019 Apr 1;74(4):1056-1061. doi: 10.1093/jac/dky539. J Antimicrob Chemother. 2019. PMID: 30590533
BACKGROUND: Posaconazole delayed-release tablets offer better bioavailability than the liquid suspension, but no post-marketing data are available in immunocompetent hosts such as those with chronic pulmonary aspergillosis (CPA). ...Forty-nine (68%) patients develop …
BACKGROUND: Posaconazole delayed-release tablets offer better bioavailability than the liquid suspension, but no post-marketing data are ava …
Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review.
Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Denning DW, et al. Clin Infect Dis. 2003 Oct 1;37 Suppl 3:S265-80. doi: 10.1086/376526. Clin Infect Dis. 2003. PMID: 12975754
We describe 18 nonimmunocompromised patients with chronic pulmonary aspergillosis. Duration of the disease ranged from several months to >12 years. ...Weight loss, chronic cough (often with hemoptysis and shortness of breath), fatigue, and chest pai …
We describe 18 nonimmunocompromised patients with chronic pulmonary aspergillosis. Duration of the disease ranged from several …
Chronic illness associated with mold and mycotoxins: is naso-sinus fungal biofilm the culprit?
Brewer JH, Thrasher JD, Hooper D. Brewer JH, et al. Toxins (Basel). 2013 Dec 24;6(1):66-80. doi: 10.3390/toxins6010066. Toxins (Basel). 2013. PMID: 24368325 Free PMC article. Review.
It has recently been demonstrated that patients who develop chronic illness after prior exposure to water damaged buildings (WDB) and mold have the presence of mycotoxins, which can be detected in the urine. We hypothesized that the mold may be harbored internally and cont …
It has recently been demonstrated that patients who develop chronic illness after prior exposure to water damaged buildings (WDB) and …
[Pilot study of intermittent administration of liposomal amphotericin B for chronic pulmonary aspergillosis].
Fujita M, Hirano R, Matsumoto T, Watanabe K. Fujita M, et al. Jpn J Antibiot. 2014 Jun;67(3):205-10. Jpn J Antibiot. 2014. PMID: 25163253 Japanese.
Treatment for chronic pulmonary aspergillosis is difficult and frequently is required for prolong period. In outpatients setting, only voriconazole and itraconazole could be used. ...Adverse events were only fatigue and short period of fever. No recurrence of …
Treatment for chronic pulmonary aspergillosis is difficult and frequently is required for prolong period. In outpatients setti …
Pathophysiological study of chronic necrotizing pulmonary aspergillosis.
Sugino K, Hasegawa C, Sano G, Shibuya K, Homma S. Sugino K, et al. Jpn J Infect Dis. 2008 Nov;61(6):450-3. Jpn J Infect Dis. 2008. PMID: 19050352 Free article.
The aim of the present study is to define the characteristics of the clinical and histopathological features of chronic necrotizing pulmonary aspergillosis (CNPA) cases with severe hemoptysis. ...All patients had fever, general fatigue, and hemoptysis, and th …
The aim of the present study is to define the characteristics of the clinical and histopathological features of chronic necrotizing p …
Interventional Procedures in Patients With Pulmonary Vascular Obstruction.
Cullivan S, Redmond K, Ridge C, O'Connell OJ. Cullivan S, et al. Ann Thorac Surg. 2019 Jan;107(1):e9-e11. doi: 10.1016/j.athoracsur.2018.05.024. Epub 2018 Jun 7. Ann Thorac Surg. 2019. PMID: 29885978
A 21-year-old patient presented with a short history of fatigue and dyspnea on a background of double-lung transplantation for cystic fibrosis and preexisting chronic superior vena cava obstruction. ...
A 21-year-old patient presented with a short history of fatigue and dyspnea on a background of double-lung transplantation for cystic …
19 results
Jump to page
Feedback